Skip to main content

Table 3 Health-state utilities and event-based disutilities applied in the analyses

From: The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal

Complication

Utility

References

Patient with type 2 diabetes baseline (no complications)

0.785

[34]

Myocardial infarction event

 − 0.055

[34]

Post-myocardial infarction

0.730

[34]

Angina

0.695

[34]

Congestive heart failure

0.677

[34]

Stroke event

 − 0.164

[34]

Post-stroke

0.621

[34]

Peripheral vascular disease

0.724

[35]

Microalbuminuria

0.785

[34]

Gross proteinuria

0.737

[35]

Hemodialysis

0.621

[36]

Peritoneal dialysis

0.581

[36]

Renal transplant

0.762

[37]

Background diabetic retinopathy

0.745

[38]

Background diabetic retinopathy (wrongly treated)

0.745

[38]

Proliferative diabetic retinopathy (laser treated)

0.715

[38]

Proliferative diabetic retinopathy (no laser treatment)

0.715

[38]

Macular edema

0.745

[38]

Severe vision loss

0.711

[34]

Cataract

0.769

[39]

Neuropathy

0.701

[35]

Healed ulcer

0.785

[34]

Active ulcer

0.615

[35]

Amputation event

− 0.280

[34]

Post-amputation

0.505

[34]

Non-severe hypoglycemic event (daytime)

− 0.004

[33]

Non-severe hypoglycemic event (nocturnal)

− 0.007

[33]

Severe hypoglycemic event (daytime)

− 0.057

[33]

Severe hypoglycemic event (nocturnal)

− 0.062

[33]

Each unit of BMI over 25 kg/m2

− 0.0061

[35]

  1. BMI: body mass index
  2. Health-state utilities are calculated as the baseline utility for type 2 diabetes with no complications plus the corresponding event-based disutilities sourced from the literature review conducted by Beaudet et al. [32]